COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NCL News Archive

Wednesday, October 16, 2019

Funding Opportunities & Translational Resources

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.

Nanotechnology-Focused:

PAR 20-284 – Innovative Research in Cancer Nanotechnology (R01... View Post


Friday, September 27, 2019

Online Workshop - Molecular & Cellular Immunology

FREE Online Workshop

MOLECULAR AND CELLULAR IMMUNOLOGY: FROM BASICS TO APPLICATIONS IN PRECLINICAL DEVELOPMENT OF NANOTECHNOLOGY-FORMULATED DRUGS

December 2-6 and 9-12, 2019—11am-1pm EST

 

This two-part on-line workshop includes lectures covering fundamental... View Post


Friday, August 16, 2019

August 2019 Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Tuesday, July 23, 2019

Facilitating API Delivery with Nanoscale Solutions

The July issue of Pharmaceutical Technology highlights nanotechnology with interviews from Young-Ho Song, a research fellow at Pfizer Oncology, and NCL’s Stephan Stern. The article, written by Cynthia Challener, touches on some of the most promising avenues for nanotech—improving the therapeutic potential of existing drugs, resurrecting previously failed drugs, developing generics of current... View Post


Tuesday, July 23, 2019

Bioequivalence Studies: Doxil vs. Sun Pharma and Abraxane vs. Genexol-PM

The NCL recently completed a 2.5 year interagency collaboration with the US Food and Drug Administration (FDA) to evaluate the bioequivalence of marketed nanomedicines. The complexity of nanomedicine drug formulations poses unique scientific challenges. And, with the influx of generic versions of several nanomedicines now nearing clinical evaluation, these formulations pose unique regulatory... View Post


Wednesday, May 15, 2019

Identifying the Risk of Infusion Reactions

The NCL has just launched a new Technical Service to assess the potential for infusion reactions. Systemic administration of nanomedicines (and other therapies) have the potential to cause infusion reactions in patients, which often delays or halts their clinical translation. These reactions can manifest as fevers, chills, rigors, rashes, chest or back pain, or difficulty breathing, and, in... View Post


Tuesday, April 9, 2019

NANOBIOTIX Announces First Ever Radioenhancer to Receive European Market Approval

Former NCL Collaborator NANOBIOTIX recently announced European market approval for their formulation Hensify® (NBTXR3). Per the press release:

Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®--a first-in-class radioenhancer--offers cancer patients an... View Post


Thursday, April 4, 2019

New Mechanistic Immunotoxicology Protocols

NCL's Immunology team has put together a series of new protocols which probe various immunotoxicology aspects of nanomedicines. The 7 new protocols have been published on the NCL Assay Cascade Protocols webpage and are available for download. They include:

 

ITA-26: Detection of Intracellular Complement Activation in Human T Lymphocytes

The complement... View Post


Tuesday, March 5, 2019

CRS Nanomedicine and Nanoscale Delivery Webinar

The Controlled Release Society’s (CRS) Nanomedicine and Nanoscale Delivery Focus Group will host their first webinar in March, given by NCL Director, Scott McNeil. This webinar will highlight the unique challenges of nanomedicine development, including the complex characterization requirements for these formulations and the hurdles of regulatory review. Having characterized more than 400... View Post


Tuesday, March 5, 2019

December 2018 Awardees Announced

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Pages